SCHEMBL5534949

SCHEMBL5534949

Cc1cccc(CC(Nc2nc3nonc3nc2Nc2ccc(Cl)c(Cl)c2)C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.46
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
TP53 P04637 3/20 0.43
CCR2 P41597 1/20 0.43
CCR5 P51681 1/20 0.43
CTSB P07858 2/20 0.42
TACR1 P25103 1/20 0.41
ITGB1 P05556 3/20 0.41
ITGA4 P13612 3/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HTT P42858 1/20 0.40
P2RX3 P56373 1/20 0.39
CDKN1A P38936 1/20 0.38
MMP2 P08253 1/20 0.38
POLB P06746 1/20 0.38
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3048432 0.83 NOS2 (0.46) FPR2MAPTSMN1; SMN2TP53CCR2
SCHEMBL3048435 0.83 NOS2 (0.46) FPR2MAPTSMN1; SMN2TP53CCR2
SCHEMBL3052199 0.78 MAPT (0.46) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL10276991 0.76 MAPT (0.45) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL3051396 0.73 TP53 (0.55) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL5539670 0.72 MAPT (0.45) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL3051775 0.71 MAPT (0.46) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL3055646 0.71 TP53 (0.58) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL5532987 0.70 MAPT (0.46) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL6217362 0.69 CTSB (0.57) MAPTTP53CTSBTACR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178754-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2012-07-12 US claimed
US-20120178754-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2012-07-12 US disclosed
EP-1799689-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-06-27 EP disclosed
WO-2006044402-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178754-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 FPR2 567/4885MAPT 3908/4885SMN1; SMN2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.